Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study.

doi:10.1007/s12282-021-01283-4

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study.

Breast cancer (Tokyo, Japan) - 1 Jan 2022

Koh Su-Jin, Ohsumi Shozo, Takahashi Masato, Fukuma Eisuke, Jung Kyung Hae, Ishida Takanori, Dai Ming-Shen, Chang Chuan-Hsun, Dalvi Tapashi, Walker Graham, Bennett James, O'Shaughnessy Joyce, Balmaña Judith

Abstract excerpt

BACKGROUND: The multinational BREAKOUT study (NCT03078036) sought to determine the prevalence of germline BRCA1/2 (gBRCA1/2) and somatic BRCA1/2 (sBRCA1/2) mutations and mutations in other homologous recombination repair (HRR) genes in women with HER2-negative metastatic breast cancer (MBC) starting first-line chemotherapy. METHODS: Genetic testing for gBRCA, sBRCA, and HRR gene mutations was performed in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ataxia Telangiectasia Mutated Proteins

Share to BRCA1 Protein

Share to BRCA2 Protein

Share to Checkpoint Kinase 2

Share to Fanconi Anemia Complementation Group N Protein

Share to Observational Studies as Topic

Share to Prevalence

Source

Open in PubMed Open full text

Identifiers

PMID: 34467476
DOI: 10.1007/s12282-021-01283-4
PMCID: PMC8732904

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study.PMID 34467476Read ↗

Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutationsSemantic proximity Read ↗

Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations.Semantic proximity Read ↗

Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real‐world databaseSemantic proximity Read ↗

Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single-Center ExperienceSemantic proximity Read ↗

Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study.Semantic proximity Read ↗

Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) StudySemantic proximity Read ↗

A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies.Semantic proximity Read ↗

Exploring the effectiveness of molecular subtypes, biomarkers, and genetic variations as first-line treatment predictors in Asian breast cancer patients: A systematic review and meta-analysisSemantic proximity Read ↗

A Systematic Review of the Prevalence of Germline BRCA mutations in North Asia Breast Cancer Patients.Semantic proximity Read ↗

Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancerSemantic proximity Read ↗

Real-World Germline BRCA Testing, Poly(ADP-ribose) Polymerase Inhibitor Utilization, and Survival Outcomes in Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.